Circumvent the Tariff challenges with an agile supply chain Consulting
Supply Chain Ecosystem Analysis now part of DBMR Reports
Global Immunotherapy Drugs Market
Market Size in USD Billion
CAGR :
%
USD
251.94 Billion
USD
601.87 Billion
2024
2032
Forecast Period
2025 –2032
Market Size(Base Year)
USD
251.94 Billion
Market Size (Forecast Year)
USD
601.87 Billion
CAGR
%
Major Markets Players
Abbott
PerkinElmer Inc.
Illumina Inc.
QIAGEN
F. Hoffmann-La Roche Ltd
Global Immunotherapy Drugs Market Segmentation, By Type of Drug (Monoclonal Antibodies, Adult Vaccines, Checkpoint Inhibitors, Interferons Alpha and Beta, Interleukins, and Other Drugs), Therapy Area (Cancer, Autoimmune and Inflammatory Diseases, Infectious Diseases, and Other Therapy Areas), End User (Hospitals, Clinics, and Other End Users) - Industry Trends and Forecast to 2032
Immunotherapy Drugs Market Size
The global immunotherapy drugs market size was valued at USD 251.94 billion in 2024 and is expected to reach USD 601.87 billion by 2032,at a CAGR of 11.50 % during the forecast period
This growth is driven by factors such as the increasing prevalence of cancer and other chronic diseases, driving the demand for immunotherapy treatments and advances in research and development leading to the introduction of new and more effective immunotherapy drugs
Immunotherapy Drugs Market Analysis
The immunotherapy drugs market is expanding as new therapies emerge, focusing on targeting specific cancer cells more efficiently and with fewer side effects. This shift is driving growth, especially in oncology treatments
Advancements in personalized medicine and the growing understanding of the immune system are allowing for more tailored treatment options, increasing the appeal of immunotherapy as a treatment choice
North America is expected to dominate the immunotherapy drugs market due to its advanced healthcare infrastructure, high adoption of innovative therapies, and the presence of major pharmaceutical companies investing heavily in immunotherapy research and development.
Asia-Pacific is expected to be the fastest growing region in the immunotherapy drugs market during the forecast period due to increasing cancer incidence, improving healthcare access, and growing government support for the development of cancer therapies in countries such as China and India.
The monoclonal antibodies segment is expected to dominate the immunotherapy drugs market with the largest share of 76.7% in 2025due to its broad applicability across various chronic and autoimmune diseases, high clinical success rates, and increasing R&D investments in biologics for targeted therapies.
Report Scope and Immunotherapy Drugs Market Segmentation
Attributes
Immunotherapy Drugs Key Market Insights
Segments Covered
By Type of Drug:Monoclonal Antibodies, Adult Vaccines, Checkpoint Inhibitors, Interferons Alpha and Beta, Interleukins, and Other Drugs
By Therapy Area: Cancer, Autoimmune and Inflammatory Diseases, Infectious Diseases, and Other Therapy Areas
By End User: Hospitals, Clinics, and Other End Users
Increasing Demand for Combination Therapies in Immunotherapy
Growing Investment in Personalized Medicine and Precision Oncology
Value Added Data Infosets
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Immunotherapy Drugs Market Trends
“Increasing Adoption of Combination Therapies”
Combination therapies are being actively investigated in clinical trials and clinical practice to achieve optimal clinical outcomes
The rationale behind combination approaches is to increase treatment effectiveness, break resistance, and address the intricacies of how the immune system reacts against diseases
For instance, in April 2024, the FDA approved the combination of N-803 with BCG for treating BCG-unresponsive non-muscle-invasive bladder cancer, based on the QUILT 3.032 clinical trial led by UCLA, which demonstrated enhanced survival and efficacy
The combination of drugs for treating particular cancer diseases drives the immunotherapy drug market
This combined approach expands the immunotherapy drugs market and provides clinicians with a more versatile toolkit for managing complex cancer cases
The rising prevalence of cancer and chronic conditions such as autoimmune and inflammatory diseases is a primary driver of the immunotherapy drugs market, with millions of new cancer cases reported each year globally
For instance, the World Health Organization (WHO) projected over 19 million new cancer cases worldwide in 2024
Immunotherapy has demonstrated strong potential in treating previously untreatable cancers such as melanoma and non-small cell lung cancer, making it a preferred treatment option for oncologists
For instance, the FDA approved nivolumab for advanced melanoma after it showed improved overall survival in clinical trials
The success of immune checkpoint inhibitors such as pembrolizumab (Keytruda) and nivolumab (Opdivo) in significantly extending survival rates in cancers such as melanoma and lung cancer supports the growing clinical trust in immunotherapy
Technological advances have expanded immunotherapy applications beyond oncology to include diseases such as rheumatoid arthritis and multiple sclerosis, increasing the scope and adoption of these therapies
Ongoing research and development are continuously generating new treatment options, such as CAR T-cell therapies, which have shown impressive results in treating relapsed or refractory blood cancers such as leukemia and lymphoma
Opportunity
“Rising Investment in Research and Development”
Rising investment in research and development by pharmaceutical companies, biotech firms, and governments is creating major opportunities in the immunotherapy drugs market as efforts intensify to discover innovative treatments for chronic diseases and cancer
Exploration into combination therapies and personalized medicine is gaining traction, allowing tailored treatments that enhance patient response rates
For instance, combining checkpoint inhibitors with chemotherapy or radiation has shown improved outcomes in certain cancers
CAR T-cell therapy, a result of advanced R&D, has revolutionized the treatment of hematological cancers such as leukemia and lymphoma, providing options for patients who previously had limited choices
Increasing breakthroughs in biomarkers and precision medicine are enabling more targeted and effective immunotherapy treatments, helping clinicians predict patient responses and minimize adverse effects
Companies focusing on R&D are expanding their product pipelines, positioning themselves to meet the growing demand for diverse treatment options and contributing to long-term market expansion
Restraint/Challenge
“High Treatment Costs and Accessibility”
The high treatment costs of immunotherapy drugs, including CAR T-cell therapies and immune checkpoint inhibitors, present a major challenge by making them unaffordable for many patients without premium insurance or government aid
Treatment expenses can run into hundreds of thousands of dollars per patient, covering not just the drug itself but also hospital stays, specialized administration, and ongoing monitoring
For instance, CAR T-cell therapies such as Kymriah have pricing that exceeds USD 400,000 in some markets
In low- and middle-income countries, limited healthcare funding and lack of insurance coverage restrict patient access to these advanced therapies, making equitable treatment distribution difficult
Reimbursement challenges add to the barrier, as policies differ drastically across regions, with some healthcare systems offering partial or no coverage for new immunotherapy treatments
A shortage of trained professionals and adequate infrastructure to safely administer immunotherapy further limits accessibility in developing and rural regions, worsening health inequities globally
Immunotherapy Drugs Market Scope
The market is segmented on the basis of type of drug, therapy area, and end user.
Segmentation
Sub-Segmentation
By Type of Drug
Monoclonal Antibodies
Adult Vaccines
Checkpoint Inhibitors
Interferons Alpha and Beta
Interleukins
Other Drugs
By Therapy Area
Cancer
Autoimmune and Inflammatory Diseases
Infectious Diseases
Other Therapy Areas
By End User
Hospitals
Clinics
Other End Users
In 2025, the monoclonal antibodies is projected to dominate the market with a largest share in type of drug segment
The monoclonal antibodies segment is expected to dominate the immunotherapy drugs market with the largest share of 76.7% in 2025due to its broad applicability across various chronic and autoimmune diseases, high clinical success rates, and increasing R&D investments in biologics for targeted therapies.
The cancer is expected to account for the largest share during the forecast period in therapy area market
In 2025, the cancer segment is expected to dominate the market with the largest market share of 91.9% due rising global incidence, increasing adoption of immunotherapy as a primary treatment option, and growing approvals of immune-based cancer drugs by regulatory authorities.
Immunotherapy Drugs Market Regional Analysis
“North America Holds the Largest Share in the Immunotherapy Drugs Market”
North America is the dominating region in the global immunotherapy drugs market, holding a market share of 49.9%
The region's dominance is driven by a high incidence of cancer and autoimmune diseases, leading to increased demand for effective treatments
Advanced healthcare infrastructure and significant investments in research and development contribute to the development of innovative therapies
Favourable healthcare policies and increased spending on health services support the adoption of immunotherapy drugs
The presence of major pharmaceutical companies and a strong industry presence further bolster the region's market position
“Asia-Pacific is Projected to Register the Highest CAGR in the Immunotherapy Drugs Market”
Asia Pacific is the fastest-growing region in the global immunotherapy drugs market, projected to grow at the highest CAGR over the forecast period
The region's growth is fuelled by a rising prevalence of cancer, particularly in countries such as India and China
Increasing healthcare expenditure and demand for advanced cancer treatments contribute to market expansion
Favourable regulatory environments and government support for research and development enhance market growth
The emergence of local players offering affordable immunotherapy drugs increases accessibility and adoption
Immunotherapy Drugs Market Share
The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.
The Major Market Leaders Operating in the Market Are:
Latest Developments in Global Immunotherapy Drugs Market
In February 2024, AbbVie (U.S.) completed its acquisition of ImmunoGen (U.S.), valued at USD 10.1 billion. The acquisition focuses on enhancing AbbVie’s oncology portfolio, particularly in antibody-drug conjugates, with ImmunoGen’s Elahere for treating platinum-resistant ovarian cancer. This development strengthens AbbVie’s position in the oncology market by adding a new targeted cancer therapy. The acquisition is expected to drive long-term revenue growth despite short-term financial impacts due to acquisition expenses
In October 2023, Roche (Switzerland) entered into a definitive agreement to acquire Telavant Holdings (U.S.) for USD 7.1 billion. The acquisition grants Roche exclusive rights to develop and commercialize RVT-3101, a promising antibody in Phase 2 trials for inflammatory bowel diseases. This move strengthens Roche's portfolio in autoimmune treatments and accelerates its ability to bring innovative therapies to market. The deal also includes an option to collaborate with Pfizer on a next-generation bispecific antibody
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
Interactive Data Analysis Dashboard
Company Analysis Dashboard for high growth potential opportunities
Research Analyst Access for customization & queries
Competitor Analysis with Interactive dashboard
Latest News, Updates & Trend analysis
Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
Claudio Rondena
Group Business Development & Strategic Marketing Director, C.O.C Farmaceutici SRL
"This morning we were involved in the first part, the data presentation of MKT analysis, selected abstract from your work. The board team was really impressed and very appreciated, as well."
David Manning - Thermo Fisher Scientific
Director, Global Strategic Accounts,
Dear Ricky, I want to thank you for the excellent market analysis (LIMS INSTALLED BASE DATA) that you and your team delivered, especially end of year on short notice.
Sachin and Shraddha captured the requirements, determined their path forward and executed quickly.
You, Sachin and Shraddha have been a pleasure to work with – very responsive, professional and thorough.
Your work is much appreciated.
Manager - Market Analytics,
Uriah D. Avila - Zeus Polymer Solutions
Thank you for all the assistance and the level of detail in the market report. We are very pleased with the results and the customization. We would like to continue to do business.
Business Development Manager,
(Pharmaceuticals Partner for Nasal Sprays) | Renaissance Lakewood LLC
DBMR was attentive and engaged while discussing the Global Nasal Spray Market. They understood what we were looking for and was able to provide some examples from the report as requested. DBMR Service team has been responsive as needed. Depending on what my colleagues were looking for, I will recommend your services and would be happy to stay connected in case we can utilize your research in the future.
Business Intelligence and Analytics,
Ipsen Biopharm Limited
We are impressed by the CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT report - so a BIG thanks to you colleagues.
Competition Analyst,
Basler Web
I just wanted to share a quick note and let you know that you guys did a really good job. I’m glad I decided to work with you. I shall continue being associated with your company as long as we have market intelligence needs.
Marketing Director,
Buhler Group
It was indeed a good experience, would definitely recommend and come back for future prospects.
COO,
A global leader providing Drug Delivery Services
DBMR did an outstanding job on the Global Drug Delivery project, We were extremely impressed by the simple but comprehensive presentation of the study and the quality of work done. This report really helped us to access untapped opportunities across the globe.
Marketing Director,
Philips Healthcare
The study was customized to our targets and needs with well-defined milestones. We were impressed by the in-depth customization and inclusion of not only major but also minor players across the globe. The DBMR Market position grid helped us to analyze the market in different dimension which was very helpful for the team to get into the minute details.
Product manager,
Fujifilms
Thankful to the team for the amazing coordination, and helping me at the last moment with my presentation. It was indeed a comprehensive report that gave us revenue impacting solution enabling us to plan the right move.
Investor relations,
GE Healthcare
Thank you for the report, and addressing our needs in such short time. DBMR has outdone themselves in this project with such short timeframe.
Market Analyst,
Medincell
We found the results of this study compelling and will help our organization validate a market we are considering to enter. Thank you for a job well done.
Andrew - Senior Global Marketing Manager,
Medtronic (US)
I want to thank you for your help with this report – It’s been very helpful in our business planning and it well organized.
Amarildo - Manager, Global Strategic Alignment
MasterCard
We believe the work done by Data Bridge Team for our requirements in the North America Loyalty Management Market was fantastic and would love to continue working with your team moving forward.
Tor Hammer
Green Nexus LLc
Thank you for your quick response to this unfortunate circumstance. Please extend my thanks to your reach team. I will be contacting you in the future with further projects
I acknowledge the difficulty given by the very short warning for this report, and I think that its quality and your delivering time have been very satisfying.
Obviously, as a provider Data Bridge Market Research will be considered as a plus for future needs of Nippon Gases.
Yuki Kopyl (Asian Business Development Department)
UENO FOOD TECHNO INDUSTRY, LTD. (JAPAN)
Xylose report was very useful for our team. Thank you very much & hope to work with you again in the future
